" class="no-js "lang="en-US"> Sonrava Health Enters Strategic Alliance with FCL Dental, Owner of One of the Nation’s Largest Independent Dental Benefits Companies - Medtech Alert
Sunday, May 19, 2024

Sonrava Health Enters Strategic Alliance with FCL Dental, Owner of One of the Nation’s Largest Independent Dental Benefits Companies

Sonrava Health has announced that it has entered into a strategic alliance with FCL Dental, a leading independent dental benefits company with proprietary dental benefit plans and provider networks.

Headquartered in Sugar Land, Texas, FCL Dental operates in 19 states and serves the dental benefit needs of employer groups, unions, government agencies, municipalities, associations and individuals through its preferred provider organization, health maintenance organization and indemnity plan designs. Its public sector business serves beneficiaries of Medicare, Medicaid and other programs in partnership with major health plans and nursing homes.

“We welcome FCL Dental team members and clients to the Sonrava Health network through this alliance,” said Daniel D. Crowley, Chairman and Chief Executive Officer of Sonrava Health. “Highlighting FCL Dental benefit plans and networks will be an increasingly important part of our strategy as we continue to participate more broadly in the healthcare ecosystem throughout the country. Our goal is to supercharge our growing proprietary network of nearly 600 hard wall offices with a wraparound PPO network of high quality, independent doctors, creating a highly attractive integrated oral health network for our clients.”

“Sonrava Health will be an ideal strategic ally as we continue to expand our plan offerings and networks and serve more clients across the country,” said James Taylor, Chief Executive Officer of FCL Dental. “This is a synergistic relationship between two longstanding oral health companies committed to creating access to high quality, affordable care.”

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more